Climb Bio financials
$11.50−2.04%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — |
| Operating income | -$15.4M | -$15.2M | -$19.3M | -$14.9M | -$10.7M | -$23.0M | -$10.9M |
| Net income | -$13.5M | -$13.7M | -$17.5M | -$12.9M | -$8.7M | -$20.8M | -$8.4M |
| Net margin | — | — | — | — | — | — | — |
| Diluted EPS | $-0.18 | $-0.20 | $-0.26 | $-0.19 | $-0.13 | $-0.31 | $-0.12 |
| EBITDA | -$15.3M | -$15.2M | -$19.3M | -$14.9M | -$10.6M | -$23.0M | -$10.9M |
| Operating cash flow | -$10.5M | -$14.4M | -$15.6M | -$12.1M | -$11.1M | -$15.4M | -$5.5M |
| Free cash flow | -$10.8M | -$14.4M | -$15.6M | -$12.2M | -$11.2M | -$15.4M | -$5.5M |
| Diluted shares | 76.2M | 68.2M | 68.2M | 68.0M | 67.6M | 67.5M | 67.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $44.1M | $8.4M | $35.7M | $25.8M | $22.7M | $29.0M |
| Short-term investments | $139.0M | $101.2M | $65.4M | $61.1M | $62.0M | $69.0M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $246.3M | $152.4M | $167.7M | $182.3M | $192.4M | $200.7M |
| Total liabilities | $6.7M | $4.3M | $7.3M | $5.3M | $6.6M | $7.4M |
| Shareholders' equity | $239.5M | $148.1M | $160.5M | $177.0M | $185.8M | $193.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology